Chen Jiemin, Cao Jianzhong, Wang Penghui, He Xiaodong
Department of General Surgery, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing 100730, P.R. China.
Department of General Surgery, Beijing Tiantan Hospital, Capital Medical University, Beijing 100070, P.R. China.
Oncol Lett. 2020 Oct;20(4):70. doi: 10.3892/ol.2020.11931. Epub 2020 Jul 29.
Reliable biomarkers for the prognosis of hepatocellular carcinoma (HCC) are rare, and novel biomarkers are required for the appropriate management of HCC. 5'-Nucleotidase domain containing 2 () acts as an oncogene in various tumors, but its functions as a biomarker have not been confirmed. Therefore, the present study aimed to resolve these functions by analyzing the prognostic value of in patients with HCC. A tissue microarray (TMA) was prepared and expression was measured via IHC staining in TMA dots. The liver cancer (LIHC) cohort in The Cancer Genome Atlas (TCGA) was enrolled as a secondary cohort. Kaplan-Meier survival analyses and Cox regression models were used for assessment of the prognostic value of . Gene set enrichment analysis (GSEA) was performed in TCGA LIHC cohort. A total of 134 patients with HCC were retrospectively enrolled in the Peking Union Medical College Hospital cohort and clinical data were collected. A total of 359 patients with HCC in TCGA were enrolled as TCGA cohort. was used as an indicator of overall survival (OS) and relapse-free survival (RFS) in multiple cohorts. In the multivariate Cox regression model, upregulation was an independent prognostic factor of OS in both cohorts. GSEA indicated the enrichment of a series of survival- and metastasis-related gene-sets, such as LEE_LIVER_CANCER_SURVIVAL_UP and LIAO_METASTASIS. Collectively, it was suggested that upregulation was associated with poor OS and RFS in HCC, and was a potential predictive marker for HCC stratification.
用于肝细胞癌（HCC）预后评估的可靠生物标志物很少见，因此需要新的生物标志物来对HCC进行恰当管理。含5'-核苷酸酶结构域2（）在多种肿瘤中作为癌基因发挥作用，但其作为生物标志物的功能尚未得到证实。因此，本研究旨在通过分析在HCC患者中的预后价值来明确这些功能。制备了组织微阵列（TMA），并通过免疫组化染色在TMA点中检测表达。癌症基因组图谱（TCGA）中的肝癌（LIHC）队列被纳入作为次要队列。采用Kaplan-Meier生存分析和Cox回归模型评估的预后价值。在TCGA LIHC队列中进行基因集富集分析（GSEA）。北京协和医院队列回顾性纳入了134例HCC患者，并收集了临床数据。TCGA中共有359例HCC患者被纳入作为TCGA队列。在多个队列中被用作总生存期（OS）和无复发生存期（RFS）的指标。在多变量Cox回归模型中，上调是两个队列中OS的独立预后因素。GSEA表明一系列与生存和转移相关的基因集富集，如LEE_LIVER_CANCER_SURVIVAL_UP和LIAO_METASTASIS。总体而言，提示上调与HCC患者较差的OS和RFS相关，并且是HCC分层的潜在预测标志物。
